Melanocytic proliferations in sundamaged
|
|
- Hilary Goodman
- 5 years ago
- Views:
Transcription
1 Atypical Spitzoid Tumor: What Does It Mean And How Should It Be Managed? Melanocytic proliferations in sundamaged skin Jane L. Messina, Jane L. Messina MD International Melanoma Pathology Working Group 4 th annual meeting Tampa, Florida November 14, 2011 Melanoma and Other Cutaneous Malignancies, Session 5 March 23, :45-9:05 am #
2 Disclosures Durect Corporation-consultant Glaxo Smith Kline-consultant 2
3 Exhibit 1 19 y/o M with lesion on posterior neck 3 diagnoses proferred: severely atypical compound melanocytic lesion with Spitzoid features, favor melanoma favor peculiar nevus with Spitzoid and congenital features but cannot r/o melanoma markedly atypical compound Spitzoid melanocytic tumor WLE and SLNbx: both negative Four years after surgery: patient develops multiple brain and lung metastases 3
4 Basic conundrum Criteria don t always predict behavior (or even SLN involvement) Misdiagnosed melanoma major issue (#1 lawsuit for dermatopathologists) Underdiagnosis Recurrence or death Loss of opportunity for adjuvant treatment Medicolegal Overdiagnosis Surgical morbidity SLNB procedure not proven to increase OS Psychological trauma Insurability 4
5 Goals Historical perspective Pathologic criteria Sentinel node issues Molecular advances Treatment algorithm
6 ?? Spitz S. Melanoma of childhood. Am J Pathol. 1948;24: Barnhill RL et al. Atypical Spitz nevi/tumor: lack of consensus for diagnosis, discrimination from melanoma, and prediction of outcome. Hum Pathol. 1999;30: Allen AC. A reorientation of the histogenesis and clinical significance of cutaneous nevi and melanomas. Cancer. 1949; 2: Smith KH, Barrett TL, Skelton HG et al. Spindle cell and epithelioid cell nevi with atypia and metastasis (malignant Spitz nevus). Am J Surg Pathol. 1989;13:
7 Atypical Spitz nevus 1969: We propose the term atypical Spitz s nevus in the same fashion as Helwig, who uses atypical for the pseudomalignant character of the atypical fibroxanthoma. 1975: Reed et al. first use term atypical Spitz nevus in American literature 1976: Helwig reports 23 young patients with metastatic melanoma and Spitz-like primary tumor, proposed better prognosis 1977: Weedon and Little put forth histologic characteristics to distinguish atypical Spitz s nevus from melanoma Helwig EB.Heath Memorial Award Lecture. Year Book Medical Publishers, Inc; 1975: Reed RJ et al. Semin Oncol, 1975;2: Weedon D, Little JH. Cancer, 1977; 40:
8 Conventional Atypical Spitz Nevus Spitz Nevus/Tumor Spitzoid melanoma??
9 Atypical Spitz Tumor Distinct entity or IDK? Large size, generally > 1.0cm Deeper extension, often involving subcutis Asymmetry, ulceration, poor circumscription Prominent pagetoid melanocytosis High cellular density and/or confluence of melanocytes Absence of maturation Increased deep/marginal mitoses (>2-6/mm 2 ) Spitzoid cytomorphology Barnhill, RL. Modern Pathol 19: S21-S33;2006. Caraco et al. Eur J Surg Oncol Oct. 2012,
10 Conventional Atypical Atypical Conventional Spitz Nevus Spitz Spitz Nevus/Tumor Nevus/Tumor Spitz Nevus Spitzoid Spitzoid melanoma melanoma
11 Atypical Spitz tumor Relevant questions What is the outcome of the reported series of AST? What is the incidence and meaning of SLN involvement? Does AST have a distinct histologic, immunohistochemical, genetic or molecular profile? How do we find the Spitzoid melanomas?
12 Atypical Spitz tumor Relevant questions What is the outcome of the reported series of AST? What is the incidence and meaning of SLN involvement? Does AST have a distinct histologic, immunohistochemical, genetic or molecular profile? How do we find the Spitzoid melanomas?
13 Death in patients with AST >300 reported cases of AST, most treated with SLN mapping Seven total deaths Ages 12,13,14, 24, 43, 46, and 50 6 had no SLNB, 1 had +SLN Raskin L et al. Am J Surg Pathol 2011;35: Ludgate MW et al. Cancer 2009;115:631-41/Cerroni L et al. Am J Surg Pathol 2010;34: /Barnhill RL et al. Hum Pathol 1999;30: / Gerami et al. Am J Surg Pathol Feb 2013;
14 AST SLN biopsy results Pts Mean age Mean depth mm 14 SLN+ rate Lohmann et al % 1/5 Su et al % 1/8 Gamblin et al n/d 33% 1/3 Urso et al % 1/3 Murali et al % 0/6 Ludgate et al % 1/27 Ghazi et al % 0/4 Cerroni et al % n/d Raskin et al % 0/8 Sepehr et al n/d 17% 0/1 Mills et al % 1/2 Caraco et al % n/a Hung et al % 0/3 Pts w/+clnd Totals % 6/70 (9%)
15 Features of SLN in AST Four series describe SLN deposits Largest series of 27: 85% had <1% nodal involvement, 62% <0.2 mm Remaining 3 series: 50% of patients had isolated parenchymal/subcapsular disease, all <2 mm Urso, Murali, Ludgate, Gamblin
16 Features of involved SLN in AST
17 Contrast: Capsular nevus cell aggregates
18 Contrast: Intratrabecular nevus cell aggregates
19
20 Melanoma micrometastasis 20
21 Features predictive of SLN involvement in AST Most series, including largest, have found no significant differences between SLN+ and SLNtumors Significant: Deep mitoses, less inflammation plasma cells 1 Mean tumor thickness 2 >6 mitoses/sq mm 3 1.Massi et al. J Am Acad Dermatol 2011;64: Murali et al. Annals of Surgical Oncology 15(1): Hung et al Human Pathology (2013) 44, 87 94
22 Outcome of AST patients with SLNB Patients Mean duration f/u in mo Recurrence beyond SLN Lohmann et al /10 0/10 Su et al /18 0/18 Gamblin et al /10 0/10 Urso et al /12 0/12 Murali et al /21 0/21 Ludgate et al /57 0/57 Ghazi et al /6 0/6 Cerroni et al /35 1/35 Raskin et al NR 0/15 0/15 Sepehr et al /6 0/6 Caraco et et /40 0/40 Mills et al /10 0/10 Hung et al /23 0/23 Totals /263 1/263 Death with metatasis
23 Meaning of SLN involvement Recurrence and death vanishingly rare in 13 series with followup ranging from 9-64 months Comparison with childhood melanoma 5 year o/s ~75% ~1/2 of recurrence/death occurs after 5 years AST could represent unique, less aggressive subtype of melanoma potentially cured by SLN removal
24 Pros and cons of SLN biopsy Diagnosis? Metastatic melanocytic tumor of uncertain malignant potential Pros Guides further therapy/monitoring May be saved more extensive surgery later Alleviates uncertainty, about 2/3 get good news May be therapeutic Cons Guides further therapy/monitoring May create unecessary anxiety
25 Case 2-HH-age : presented to pediatrician with longstanding mole since birth, biopsied and told benign 1999: mother went to MCC presentation and noted similarities to daugher s mole, prompting rebiopsy: diagnosis of malignant melanoma of back, Clark IV, 3.4 mm in depth Underwent WLE and SLNB No residual tumor 0/3 +SLN right neck 1/11 +SLN right axilla
26 14 y/o F with 3.4 mm melanoma of back L axilla SLN 9
27 Same patient 10 years after CLND and adjuvant interferon
28 Atypical Spitz tumor Relevant questions What is the outcome of the reported series of AST? What is the incidence and meaning of SLN involvement? Does AST have a distinct histologic, immunohistochemical, genetic or molecular profile? How do we find the Spitzoid melanomas?
29 Fluorescence in situ hybridization Initial four-probe assay (6p25, Cep6, 6q23, 11q13) tested on unequivocal neoplasms: sensitivity 87%, specificity 95% Newer four-probe assay with 6p25, 8q24, 9p21, 11q13: sens. 94%, spec. 98% Polyploidy: 10% of typical Spitz have balanced gains in all four probe sets (3-4x) Isaac et al. Am J Dermatopathol 2010;32:
30 FISHing for ASTs Original assay 25 typical and atypical Spitz with known outcome (4 deaths/advanced logoregional disease) 24% of cases FISH positive (3 had <5 year f/u) 100% sensitive, 57% specific 16 AST with long-term outcome (1 death) All negative (0% sensitive, 0% specific) Massi et al. J Am Acad Dermatol 2011;64: Raskin et al. Am J Surg Pathol 2011;35:
31 FISHing for ASTs Newer assay Recently tested on 75 AST 64 uneventful 5 year f/u, 11 with advanced locoregional disease, distant metastasis or death All 11 patients with advanced disease had abnormality of at least one locus 9 showed deletions of 9p21-most significant and only feature predictive of death However, 24.3% of patients with uneventful follow up had a positive result Sensitivity 100%, specificity 74% Gerami et al, Am J Surg Pathol, Feb 2013
32 Comparative genomic hybridization 95% of melanomas harbor numerous chromosomal gains and losses Nevi rarely show aberrations 15% of Spitz nevi (esp. recurrent) have 11p or 7q gain 7/16 AST had abnormalities (esp. 1p, 9 loss or gain, none in chromosomes evaluated by FISH) Bastian BC et al. J Invest Dermatol. 1999;113: Bastian BC et al. Am J Pathol. 2003;163: Raskin et al. Am J Surg Pathol 2011;35:
33 Molecular characteristics of AST BRAF: 0-75% found in 54 lesions tested in four series 0/7, 12/16, 1/16, 2/15 HRAS: 15% (4/26) in two series NRAS: 6% (2/31) in two series Raskin et al. Am J Surg Pathol 2011;35: Massi et al. J Am Acad Dermatol 2011;64: Takata et al. British Journal of Dermatology , pp Fullen et al. Mod Pathol 2006;19:
34 Immunohistochemical staining Ki-67 for proliferative activity: >10% favors melanoma, <10% does not exclude phh3 for mitoses HMB-45 for maturation BAP1 if multiple lesions P16 loss, BRAFv600E significance unclear Nasr MR, El-Zammar O. Am J Dermatopathol. Apr 2008;30(2): Ohsie et al. J Cutan Pathol 2008; 35:
35 Ki-67: the good, the bad, and the ugly
36 Phosphohistone H3 stains cells in mitosis
37 p16 and malignant potential p16:multiple studies show loss in 50-98% of melanoma Loss of p16 in 6/6 childhood Spitzoid melanoma, but present in 18/18 Spitz nevi and 12/12 melanocytic nevi Recently, present in 15/19 (79%) Spitzoid melanoma and 83% Spitz Al Dhaybi R et al J Am Acad Dermatol. Aug 2011;65(2): Ohsie et al. J Cutan Pathol 2008; 35: Mason et al. J Cutan Pathol 2012; 39(12):
38 Loss of p16 in childhood melanoma
39 Loss of p16 in childhood melanoma
40 p16 stains childhood Spitz nevi
41 HMB-45 Diminished staining with dermal depth in most benign nevi including Spitz Stains entire dermal component of melanoma Ohsie et al. J Cutan Pathol 2008; 35:
42 HMB-45 staining in nevus
43 Atypical Spitz tumor Relevant questions What is the outcome of the reported series of AST? What is the incidence and meaning of SLN involvement? Does AST have a distinct histologic, immunohistochemical, genetic or molecular profile? How do we find the Spitzoid melanomas?
44 Summary Atypical Spitz tumor: What does it mean and how is it managed? Increasingly recognized melanocytic neoplasm which deviates from typical benign Spitz but does not seem to have a distinctive molecular or genetic profile Most common in children and young adults Frequent but low-volume SLN metastasis Low recurrence rate with relatively long-term followup 44
45 Summary Atypical Spitz tumor: What does it mean and how is it managed? Workup should include expert consultation, molecular analysis by FISH and/or CGH Recommend wide excision and SLN biopsy until reliable test to exclude melanoma is available
Vernon K. Sondak. Department of Cutaneous Oncology Moffitt Cancer Center Tampa, Florida
Vernon K. Sondak Department of Cutaneous Oncology Moffitt Cancer Center Tampa, Florida Australasian Melanoma Conference 2016 Sydney, NSW, Australia October 29, 2016 Disclosures Dr. Sondak is a compensated
More informationCase 26 Male 37. Right jawline 5mm nodule?keloid. The best diagnosis is:
Case 26 Male 37. Right jawline 5mm nodule?keloid. The best diagnosis is: A. Desmoplastic Spitz naevus B. Atypical Spitz Tumour C. Spitzoid melanoma D. Deep penetrating naevus E. Spitz naevus Case 26: M
More informationManagement of pediatric melanocytic lesions
Open Journal of Clinical & Medical Case Reports Management of pediatric melanocytic lesions Volume 3 (2017) Issue 8 ISSN 2379-1039 Jin Kim, BS; Emmanuel Gabriel MD, PhD; Weiguo Liu MD, PhD; Lin Lin MD,
More informationThere is NO single Melanoma Stain. > 6000 Mutations in Melanoma. What else can be done to discriminate atypical nevi from melanoma?
Las Vegas Fall Clinical 2016: The Assessment and Diagnosis of Melanoma Whitney A. High, MD, JD, MEng Associate Professor, Dermatology & Pathology Director of Dermatopathology (Dermatology) University of
More informationMelanocytic Lesions: Use of Immunohistochemistry and Special Studies Napa Valley 2018
Melanocytic Lesions: Use of Immunohistochemistry and Special Studies Napa Valley 2018 Victor G. Prieto, MD, PhD Professor Depts. of Pathology and Dermatology University of Texas - MD Anderson Cancer Center
More informationGenetic Testing: When should it be ordered? Julie Schloemer, MD Dermatology
Genetic Testing: When should it be ordered? Julie Schloemer, MD Dermatology Outline Germline testing CDKN2A BRCA2 BAP1 Somatic testing Gene expression profiling (GEP) BRAF Germline vs Somatic testing
More informationMichael T. Tetzlaff MD, PhD
Molecular alterations informing the diagnosis of melanocytic tumors Michael T. Tetzlaff MD, PhD Associate Professor Department of Pathology, Section of Dermatopathology Department of Translational and
More information6/22/2015. Original Paradigm. Correlating Histology and Molecular Findings in Melanocytic Neoplasms
6 Correlating Histology and Molecular Findings in Melanocytic Neoplasms Pedram Gerami MD, Associate Professor of Dermatology and Pediatrics at Northwestern University Disclosures: I have been a consultant
More informationThe Enigmatic Spitz Lesion
The Enigmatic Spitz Lesion The Dawn of Spitz S Spitz Sophie Spitz Melanomas of Childhood ; Am J Pathol 1948 1910-1956 13 children (18 mo - 12 yrs) 12/13 had a benign clinical course Sophie Spitz Born 1910
More informationMelanoma and the genes: Molecular alterations informing the diagnosis of melanocytic tumors
Melanoma and the genes: Molecular alterations informing the diagnosis of melanocytic tumors Michael T. Tetzlaff MD, PhD Associate Professor Department of Pathology, Section of Dermatopathology Department
More informationA PRACTICAL APPROACH TO ATYPICAL MELANOCYTIC LESIONS BIJAN HAGHIGHI M.D, DIRECTOR OF DERMATOPATHOLOGY, ST. JOSEPH HOSPITAL
A PRACTICAL APPROACH TO ATYPICAL MELANOCYTIC LESIONS BIJAN HAGHIGHI M.D, DIRECTOR OF DERMATOPATHOLOGY, ST. JOSEPH HOSPITAL OBJECTIVES Discuss current trends and changing concepts in our understanding of
More informationPage 1 of 3. We suggest the following changes:
Page 1 of 3 Loren E. Clarke, M.D. Myriad Genetic Laboratories, Inc. 320 Wakara Way, Salt Lake City, UT 84108 Phone: 801.883.3470 Email: lclarke@myriad.com Date of Request: June 2017 NCCN Guidelines Panel:
More informationTime to reconsider Spitzoid neoplasms?
DERMATOLOGY PRACTICAL & CONCEPTUAL www.derm101.com Time to reconsider Spitzoid neoplasms? Carmelo Urso 1 1 Department of Anatomic Pathology, Dermatopathology Section, SM Annunziata Hospital, AUSL Toscana
More informationDavid B. Troxel, MD. Common Medicolegal Situations: Misdiagnosis of Melanoma
Common Medicolegal Situations: Misdiagnosis of Melanoma David B. Troxel, MD Medical Director, The Doctors Company, Napa, California Clinical Professor Emeritus, University of California at Berkeley Past
More informationUpdate on Spitzoid and Blue nevus-like melanocytic lesions Emphasis on molecular studies informing diagnosis, prognosis and therapy
Update on Spitzoid and Blue nevus-like melanocytic lesions Emphasis on molecular studies informing diagnosis, prognosis and therapy Michael T. Tetzlaff MD, PhD Associate Professor Department of Pathology,
More informationIntegrating Fluorescence in situ Hybridization and Genomic Array Results into the Diagnostic Workup of Melanoma
Integrating Fluorescence in situ Hybridization and Genomic Array Results into the Diagnostic Workup of Melanoma Association for Molecular Pathology United States and Canadian Academy of Pathology Companion
More informationMolecular Methods in the Diagnosis and Prognostication of Melanoma: Pros & Cons
Molecular Methods in the Diagnosis and Prognostication of Melanoma: Pros & Cons Ben J. Friedman, MD Senior Staff Physician Department of Dermatology Department of Pathology and Laboratory Medicine Henry
More informationMAPK Pathway. CGH Next Generation Sequencing. Molecular Tools in Care of Patients with Pigmented Lesions 7/20/2017
Molecular Tools in Care of Patients with Pigmented Lesions Tammie Ferringer, MD Geisinger Medical Center, Danville, PA tferringer@geisinger.edu DISCLOSURE OF RELATIONSHIPS WITH INDUSTRY Tammie Ferringer,
More informationThe Pathology of Neoplasia Part II
The Pathology of Neoplasia Part II February 2018 PAUL BOGNER, MD A S S O C I A T E P R O F E S S O R O F O N C O L O G Y P A T H O L O G Y A N D D E R M A T O L O G Y Clinical goals of cancer pathology
More informationWays to get into trouble, ideas on avoiding trouble, and diagnostic approaches to keep trouble at bay
Pitfalls in the diagnosis of melanocytic tumors Timothy McCalmont, MD University of California, San Francisco Ways to get into trouble, ideas on avoiding trouble, and diagnostic approaches to keep trouble
More informationDermatologica Sinica
DERMATOLOGICA SINICA 30 (2012) 57e61 Contents lists available at SciVerse ScienceDirect Dermatologica Sinica journal homepage: http://www.derm-sinica.com CASE REPORT Pigmented epithelioid melanocytoma:
More informationDesmoplastic Melanoma R/O BCC. Clinical Information. 74 y.o. man with lesion on left side of neck r/o BCC
R/O BCC Sabine Kohler, M.D. Professor of Pathology and Dermatology Dermatopathology Service Stanford University School of Medicine Clinical Information 74 y.o. man with lesion on left side of neck r/o
More informationConflict of Interest 9/2/2014. Pathogenesis and Comparison of Atypical Spitz Nevi vs Benign Spitz, and Childhood Melanoma
Pathogenesis and Comparison of Atypical Spitz Nevi vs Benign Spitz, and Childhood Melanoma Martin C. Mihm Jr., M.D., F.A.C.P. Harvard Medical School Brigham and Women s Hospital Dana Farber Cancer Center
More informationMelanoma Update: 8th Edition of AJCC Staging System
Melanoma Update: 8th Edition of AJCC Staging System Rosalie Elenitsas, M.D. Professor of Dermatology Director, Dermatopathology University of Pennsylvania DISCLOSURE OF RELATIONSHIPS WITH INDUSTRY None
More informationControversies and Questions in the Surgical Treatment of Melanoma
Controversies and Questions in the Surgical Treatment of Melanoma Giorgos C. Karakousis, M.D. Assistant Professor of Surgery Division of Endocrine and Oncologic Surgery University of Pennsylvania School
More informationDermatopathology. Dr. Rafael Botella Estrada. Hospital La Fe de Valencia
Dermatopathology Dr. Rafael Botella Estrada. Hospital La Fe de Valencia Melanoma and mimics Dr. Martin Mihm Malignant lesions result from the accumulation of mutations Class I lesions (benign) Class II
More informationMelanoma Patients and the Sentinel Lymph Node (SLN) Procedure: An Oncologic Surgeon s Perspective
Melanoma Patients and the Sentinel Lymph Node (SLN) Procedure: An Oncologic Surgeon s Perspective Giorgos C. Karakousis, M.D. Associate Professor of Surgery Hospital of the University of Pennsylvania Disclosures
More informationDesmoplastic Melanoma: Surgical Management and Adjuvant Therapy
Desmoplastic Melanoma: Surgical Management and Adjuvant Therapy Dale Han, MD Assistant Professor Department of Surgery Section of Surgical Oncology No disclosures Background Desmoplastic melanoma (DM)
More informationUpdate on SLN and Melanoma: DECOG and MSLT-II. Gordon H. Hafner, MD, FACS
Update on SLN and Melanoma: DECOG and MSLT-II Gordon H. Hafner, MD, FACS No disclosures The surgery of malignant disease is not the surgery of organs, it is of the lymphatic system. Lord Moynihan Lymph
More informationFemale 18. Deeply pigmented lesion on trunk.?warty naevus?seborrhoeic keratosis?malignant melanoma. The best diagnosis is:
Female 18. Deeply pigmented lesion on trunk.?warty naevus?seborrhoeic keratosis?malignant melanoma. The best diagnosis is: A. deep penetrating naevus B. naevoid malignant melanoma C. pigment synthesising
More information10/2/17. MELTUMP, SAMPUS, AST.An Algorithmic Approach to Challenging (Often Borderline) Melanocytic Tumors. An Introduction to SNP Arrays
MELTUMP, SAMPUS, AST.An Algorithmic Approach to Challenging (Often ) Melanocytic Tumors An Introduction to SNP Arrays Rajiv M. Patel, M.D. RCPA NZ ASM 2017 (11:45-12:30pm, Saturday, 23-09-17) Why do we
More informationDiagnosis of melanocytic proliferations remains one of
Update on Fluorescence In Situ Hybridization in Melanoma State of the Art Pedram Gerami, MD; Artur Zembowicz, MD, PhD N Context. Recent advances in understanding the molecular basis of melanoma have resulted
More informationUpdates on Melanoma: Are You Following the Latest Guidelines of Care? Jerry Brewer, MD
Updates on Melanoma: Are You Following the Latest Guidelines of Care? Jerry Brewer, MD Disclosure Statement Update on Melanoma Are You Following the Latest Guidelines of Care? I, Jerry D. Brewer, MD, do
More informationMolecular Aspects of Melanocytic Neoplasia. Iwei Yeh MD, PhD University of California, San Francisco
Molecular Aspects of Melanocytic Neoplasia Iwei Yeh MD, PhD University of California, San Francisco Thanks to: Boris Bastian Timothy McCalmont Philip LeBoit Beth Ruben Jeff North Laura Pincus Thaddeus
More information> 6000 Mutations in Melanoma. Tests That Cay Be Employed. FISH for Additions/Deletions. Comparative Genomic Hybridization
Winter Clinical 2017: The Assessment and Diagnosis of Melanoma Whitney A. High, MD, JD, MEng Associate Professor, Dermatology & Pathology Director of Dermatopathology (Dermatology) University of Colorado
More informationA diagnostic algorithm for atypical spitzoid tumors: guidelines for immunohistochemical and molecular assessment
Modern Pathology (2016), 1 15 2016 USCAP, Inc All rights reserved 0893-3952/16 $32.00 1 A diagnostic algorithm for atypical spitzoid tumors: guidelines for immunohistochemical and molecular assessment
More informationTranslating Evidence into Practice: Primary Cutaneous Melanoma Guidelines. Sentinel Lymph Node Biopsy
American Academy of Dermatology 2018 Annual Meeting San Diego, CA, February 17, 2018 Translating Evidence into Practice: Primary Cutaneous Melanoma Guidelines. Sentinel Lymph Node Biopsy Christopher Bichakjian,
More informationToby Maurer, MD University of California, San Francisco. Lifetime risk of an American developing melanoma
Distinguishing Pigmented Skin Lesions and Melanoma Toby Maurer, MD University of California, San Francisco Epidemiology of Melanoma Lifetime risk of an American developing melanoma 1935: 1 in 1500 1980:
More informationCutaneous Melanoma: Epidemiology (USA) The Sentinel Node in Head and Neck Melanoma. Cutaneous Melanoma: Epidemiology (USA)
The Sentinel Node in Head and Neck Melanoma Cutaneous Melanoma: Epidemiology (USA) 6 th leading cause of cancer among men and women 68,720 new cases of invasive melanoma in 2009 8,650 deaths from melanoma
More informationIntroduction. Cesinaro A M, Schirosi L, Bettelli S, Migaldi M & Maiorana A (2010) Histopathology 57,
Histopathology 2010, 57, 515 527. DOI: 10.1111/j.1365-2559.2010.03653.x Alterations of 9p21 analysed by FISH and MLPA distinguish atypical spitzoid melanocytic tumours from conventional Spitz s nevi but
More informationRebecca Vogel, PGY-4 March 5, 2012
Rebecca Vogel, PGY-4 March 5, 2012 Historical Perspective Changes In The Staging System Studies That Started The Talk Where We Go From Here Cutaneous melanoma has become an increasingly growing problem,
More informationMelanocytic lesions on Genital Skin Melanoma vs. Melanocytic Nevus, Revisited. Timothy H. McCalmont, MD University of California, San Francisco
Melanocytic lesions on Genital Skin Melanoma vs. Melanocytic Nevus, Revisited Timothy H. McCalmont, MD, San Francisco I. IS IT BENIGN OR IS IT MALIGNANT? One of the commonest determinations we make as
More informationDisclosures. SLNB for Melanoma 25/02/2014 SENTINEL LYMPH NODE BIOPSY FOR MELANOMA: CURRENT GUIDELINES AND THEIR CLINICAL APPLICATION
8 th Canadian Melanoma Conference February 22, 2014 Rimrock Resort Hotel, Banff, Alberta SENTINEL LYMPH NODE BIOPSY FOR MELANOMA: CURRENT GUIDELINES AND THEIR CLINICAL APPLICATION Christopher Bichakjian,
More informationTopics for Discussion. Malignant Melanoma. Surgical Treatment. Current Treatment of Cutaneous Melanoma 5/17/2013. Lymph Regional nodes:
Topics for Discussion What is a sentinel lymph node (SLN)? Utility of sentinel lymph biopsies: therapeutic or staging? Current Treatment of Cutaneous Melanoma Carlos Corvera, M.D. Associate Professor of
More informationMichael T. Tetzlaff MD, PhD
American Joint Cancer Committee (AJCC) staging system for primary cutaneous melanoma (8 th Edition) and principles of sentinel lymph node evaluation Emphasis on concise and accurate reporting of primary
More informationMaligna Melanoma and Atypical Fibroxanthoma: An Unusual Collision Tumour G Türkcü 1, A Keleş 1, U Alabalık 1, D Uçmak 2, H Büyükbayram 1 ABSTRACT
Maligna Melanoma and Atypical Fibroxanthoma: An Unusual Collision Tumour G Türkcü 1, A Keleş 1, U Alabalık 1, D Uçmak 2, H Büyükbayram 1 ABSTRACT Two different neoplasia in the same biopsy material called
More information21/07/2017. The «gray zone» of diagnosis is visible. Nevus Atypical nevus Melanoma. Melanoma ex-blue nevus
Update on the Clinico- Pathological and Molecular Diagnosis of Melanocytic Lesions None to declare Conflicts of interest Belfast pathology Arnaud de la Fouchardière MD, PhD Lyon, France What is new? Today
More informationToby Maurer, MD University of California, San Francisco. Lifetime risk of an American developing melanoma
Distinguishing Pigmented Skin Lesions and Melanoma Toby Maurer, MD University of California, San Francisco Epidemiology of Melanoma Lifetime risk of an American developing melanoma 1935: 1 in 1500 1980:
More informationI have no relevant conflicts of interest to disclose. John T. Seykora MD PhD Departments of Dermatology & Pathology and Laboratory Medicine
Molecular Characterization of Stage 1-3 Melanoma: Are we close to accurate prognostication and prediction? I have no relevant conflicts of interest to disclose. John T. Seykora MD PhD Departments of Dermatology
More informationMelanoma Quality Reporting
Melanoma Quality Reporting September 1, 2013 December 31, 2016 Laurence McCahill, MD Surgical Oncologist Metro Health Surgical Oncology Metro Health Professional Building 2122 Health Drive SW Wyoming,
More informationDiagnoses of Cases 1. Lentigo, other melanosis and the acquired nevus 2. Variations on the acquired nevus 3. Dermal melanocytosis
Diagnoses of Cases 1. Lentigo, other melanosis and the acquired nevus 1 1A. Lentigo simplex 4 1B. Psoralens and ultraviolet A (PUVA) lentigo 6 1C. Solar lentigo 8 1D. Café au lait macule 10 1E. Ink-spot
More informationWork-up/Follow-up: Baseline and Surveillance Studies for Cutaneous Melanoma Patients
2018 AAD Annual Meeting, San Diego, CA Work-up/Follow-up: Baseline and Surveillance Studies for Cutaneous Melanoma Patients Susan M. Swetter, MD, FAAD Professor of Dermatology Director, Pigmented Lesion
More informationBRAF, NRAS and HRAS mutations in spitzoid tumours and their possible pathogenetic significance
DERMATOPATHOLOGY BJD British Journal of Dermatology BRAF, NRAS and HRAS mutations in spitzoid tumours and their possible pathogenetic significance P.D. Da Forno, J.H. Pringle,* A. Fletcher, M. Bamford,
More informationK Blessing, J J H Grant, D S A Sanders, M M Kennedy, A Husain, P Coburn
J Clin Pathol 2000;53:591 595 591 Papers Pathology, Aberdeen University, Foresterhill, Aberdeen AB25 2ZD, K Blessing Pathology, Birmingham University, Birmingham B15 2TT, D S A Sanders Pathology, Heartlands
More informationSimulators of melanoma
Simulators of melanoma Philip E. LeBoit, M.D. Depts. of Pathology and Dermatology University of California, San Francisco Simulators of melanoma Simulators of melanoma in situ Melanocytic Non-melanocytic
More informationSpringer Healthcare. Staging and Diagnosing Cutaneous Melanoma. Concise Reference. Dirk Schadendorf, Corinna Kochs, Elisabeth Livingstone
Concise Reference Staging and Diagnosing Cutaneous Melanoma Dirk Schadendorf, Corinna Kochs, Elisabeth Livingstone Extracted from Handbook of Cutaneous Melanoma: A Guide to Diagnosis and Treatment Published
More informationWe are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors
We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists 3,500 108,000 1.7 M Open access books available International authors and editors Downloads Our
More informationDifficulties in the diagnosis of spitzoid melanocytic lesions
For reprint orders, please contact reprints@expert-reviews.com Difficulties in the diagnosis of spitzoid melanocytic lesions Expert Rev. Dermatol. 5(5), 549 560 (2010) Stephen H Olsen 1, Rajiv M Patel
More informationAssociate Clinical Professor of Dermatology MUSC
Re-excision of Moderately Dysplastic Nevi: Should we or shouldn t we? John C. Maize, Jr, M.D. Dermatologist and Dermatopathologist Trident Dermatology, Charleston SC Associate Clinical Professor of Dermatology
More informationWhitney A. High, MD, JD, MEng
ADS Dermatopathology Meeting 2014 Selected Adnexal Tumors Whitney A. High, MD, JD, MEng Associate Professor, Dermatology & Pathology Director of Dermatopathology (Dermatology) University of Colorado School
More informationCase RAC7783. M46. Ear. Mole. r/o MM.?Blue naevus RAC7783
Case RAC7783. M46. Ear. Mole. r/o MM.?Blue naevus RAC7783 Pie Chart Participants N=74 Benign: 48 N=74 Blue naevus: 38 Intradermal: 12 DPN: 10 Compound 3 Clonal: 3; Spitz 2; Special Site: 1; Congenital:
More informationWorld Articles of Ear, Nose and Throat Page 1
World Articles of Ear, Nose and Throat ---------------------Page 1 Primary Malignant Melanoma of the Tongue: A Case Report Authors: Nanayakkara PR*, Arudchelvam JD** Ariyaratne JC*, Mendis K*, Jayasekera
More informationWhich melanoma patients benefit from genetic testing?
Which melanoma patients benefit from genetic testing? Michael A. Marchetti, MD Assistant Attending, Dermatology Service Memorial Sloan Kettering Cancer Center American Academy of Dermatology Annual Meeting
More informationBlue Melanocytic Proliferations
Blue Melanocytic Proliferations Labib R. Zakka M.D., M.A. Research Fellow Melanoma Program Department of Dermatology Brigham and Women s Hospital Harvard Medical School Conflicts of Interest No conflicts
More informationSociety for Pediatric Pathology Spring Meeting Joint Symposium with American Society of Dermatopathology
Society for Pediatric Pathology 2013 Spring Meeting Joint Symposium with American Society of Dermatopathology Update on Cutaneous Melanocytic, Mesenchymal and Lymphoproliferative Lesions in Children Melanocytic
More informationEpithelial Cancer- NMSC & Melanoma
Epithelial Cancer- NMSC & Melanoma David Chin MB, BCh, BAO, LRCP, LRCS (Ireland) MCh(MD), PhD (UQ), FRCS, FRACS (Plast) Plastic & Reconstructive Surgeon Visiting Scientist Melanoma Genomic Group & Drug
More informationWHAT DOES THE PATHOLOGY REPORT MEAN?
Melanoma WHAT IS MELANOMA? Melanoma is a type of cancer that affects cells called melanocytes. These cells are found mainly in skin but also in the lining of other areas such as nose and rectum, and also
More informationCutaneous Malignancies: A Primer COPYRIGHT. Marissa Heller, M.D.
Cutaneous Malignancies: A Primer Marissa Heller, M.D. Associate Director of Dermatologic Surgery Department of Dermatology Beth Israel Deaconess Medical Center December 10, 2016 Skin Cancer Non-melanoma
More informationBAP-oma & BEYOND MICHAEL A NOWAK, MD
BAP-oma & BEYOND MICHAEL A NOWAK, MD CONFLICTS No conflicts with the content of this lecture BAP-oma Wiesner 2011: Families with multiple tan dome-shaped papules of head, neck, trunk, and extremities.
More informationMorphologic characteristics of nevi associated with melanoma: a clinical, dermatoscopic and histopathologic analysis
DERMATOLOGY PRACTICAL & CONCEPTUAL www.derm101.com Morphologic characteristics of nevi associated with melanoma: a clinical, dermatoscopic and histopathologic analysis Temeida Alendar 1, Harald Kittler
More informationDesmoplastic Melanoma: Clinical Behavior and Management Implications
Desmoplastic Melanoma: Clinical Behavior and Management Implications Collier S. Pace, MD, a Jyoti P. Kapil, MD, b Luke G. Wolfe, MS, c Brian J. Kaplan, MD, c and James P. Neifeld, MD c a Division of Plastic
More informationUpdate on Cutaneous Mesenchymal Tumors. Thomas Brenn
Update on Cutaneous Mesenchymal Tumors Thomas Brenn Cutaneous Mesenchymal Tumours Wide morphological and biological spectrum Myofibroblastic, smooth muscle, neural, vascular, apidocytic, undifferentiated;
More informationManagement of Atypical Pigmented Lesions
Management of Atypical Pigmented Lesions Jennifer A. Stein MD, PhD Associate Director, Pigmented Lesion Section Ronald O. Perelman Department of Dermatology NYU Langone Medical Center July 29, 2017 1-4
More informationUpdate on Lymph Node Management in Melanoma
Update on Lymph Node Management in Melanoma John T. Vetto MD, FACS Professor of Surgery Division of Surgical Oncology Oregon Health & Science University Portland, Oregon Lymph Nodes in Melanoma Outline
More informationFinancial disclosures
Mesenchymal Neoplasms with Melanocytic Differentiation By Konstantinos Linos MD, FCAP, FASDP Bone, Soft Tissue and Dermatopathology Assistant Professor of Pathology Dartmouth-Hitchcock Medical Center Geisel
More informationConflicts of Interest
Challenging Melanocytic Lesions Carlos N. Prieto-Granada M.D. Assistant Professor University of Alabama at Birmingham (UAB) Department of Pathology 2017 AAD Annual Meeting 3/2/17 - Orlando, FL None Conflicts
More informationImpact of Prognostic Factors
Melanoma Prognostic Factors: where we started, where are we going? Impact of Prognostic Factors Staging Management Surgical intervention Adjuvant treatment Suraj Venna, MD Assistant Clinical Professor,
More informationMELANOMA IN ADOLESCENTS AND YOUNG ADULTS
Cancer in Adolescents and Young Adults (AYA) Working Group MELANOMA IN ADOLESCENTS AND YOUNG ADULTS Emmanouil Saloustros MD, DSc General Hospital of Heraklion Venizelio Heraklion, Crete, Greece ESMO Preceptorship
More informationMolecular Enhancement of Sentinel Node Evaluation
Cochran Illustrations 060104 Molecular Enhancement of Sentinel Node Evaluation Alistair Cochran, MD and Rong Huang MD Departments of Pathology and Laboratory Medicine and Surgery, David Geffen School of
More informationSentinel Lymph Node Biopsy in Other Tumours: Sentinel Lymph Node Biopsy in Other Tumours. Methodology. Results. Key Questions to Consider
Sentinel Lymph Node Biopsy in Other Tumours Dr. Rona Cheifetz Surgical Oncology Update November 24, 2006 Sentinel Lymph Node Biopsy in Other Tumours: An Operation Looking for an Application Dr. Rona Cheifetz
More informationCutaneous Mesenchymal Neoplasms with EWSR1 Rearrangement
Cutaneous Mesenchymal Neoplasms with EWSR1 Rearrangement By Konstantinos Linos MD, FCAP, FASDP Bone, Soft Tissue and Dermatopathology Assistant Professor of Pathology Dartmouth-Hitchcock Medical Center
More informationAJCC 8 Implementation January 1, 2018 Melanoma of the Skin. Suraj Venna
AJCC 8 Implementation January 1, 2018 Melanoma of the Skin Suraj Venna Personalized Medicine AJCC 8 th Edition This Time It s Personal Traditional AJCC (TNM) population-based analyses of large databases
More informationMelanoma Underwriting Presented at 2018 AHOU Conference. Hank George FALU
Melanoma Underwriting Presented at 2018 AHOU Conference Hank George FALU MELANOMA EPIDEMIOLOGY 70-80,000 American cases annually Majority are in situ or thin > 20% are diagnosed age 45 8-9,000 melanoma
More informationIdentifying Skin Cancer. Mary S. Stone MD Professor of Dermatology and Pathology University of Iowa Carver College of Medicine March, 2018
Identifying Skin Cancer Mary S. Stone MD Professor of Dermatology and Pathology University of Iowa Carver College of Medicine March, 2018 American Cancer Society web site Skin Cancer Melanoma Non-Melanoma
More information2/6/2018. Original Paradigm. Clonal Chromosomal A berrations. Only 20% of Spitz Nevi 95% 6p, 7q, 17q, 20q, 4q,8q, 1q, 11q. Isolated Gain in 11p
Molecular Diagnostics for Melanocytic Neoplasms: Moving towards a Revolution in the Management of Melanocytic Neoplasms Pedr am Gerami MD Associate Professor of Dermatology, Pathology and Pediatrics at
More informationDr Rosalie Stephens. Mr Richard Martin. Medical Oncologist Auckland City Hospital Auckland
Dr Rosalie Stephens Medical Oncologist Auckland City Hospital Auckland Mr Richard Martin General Surgeon Melanoma Unit Team Waitemata District Health Board Auckland 8:30-9:25 WS #99: Interactive Case Studies
More informationUpdate on 8 th Edition Cutaneous AJCC Staging of Primary Cutaneous Melanoma. Michael T. Tetzlaff MD, PhD
Update on 8 th Edition Cutaneous AJCC Staging of Primary Cutaneous Melanoma Michael T. Tetzlaff MD, PhD Associate Professor Departments of Pathology (Dermatopathology) and Translational and Molecular Pathology
More informationDiploma Examination. Dermatopathology: First paper. Tuesday 20 March Candidates must answer FOUR questions. Time allowed: 3 hours
Dermatopathology: First paper Tuesday 20 March 2018 Candidates must answer FOUR questions Time allowed: 3 hours 1. Give an account of the genetic aberrations encountered in Spitzoid neoplasms and how these
More informationCase 231: F7. Exophytic naevus over left trapezious. Grown over a few weeks. Iniitally flat.?spitz naevus,?malignant
Case 231: F7. Exophytic naevus over left trapezious. Grown over a few weeks. Iniitally flat.?spitz naevus,?malignant Dermoscopy: coarse vascular structures. c/o A, B, C RAC7750 Case 231: F7. Exophytic
More informationArtur Zembowicz, MD, PhD; Sung-Eun Yang, MD; Antonios Kafanas, MD; Stephen R. Lyle, MD, PhD
Correlation Between Histologic Assessment and Fluorescence In Situ Hybridization Using MelanoSITE in Evaluation of Histologically Ambiguous Melanocytic Lesions Artur Zembowicz, MD, PhD; Sung-Eun Yang,
More informationProtocol applies to melanoma of cutaneous surfaces only.
Melanoma of the Skin Protocol applies to melanoma of cutaneous surfaces only. Procedures Biopsy (No Accompanying Checklist) Excision Re-excision Protocol revision date: January 2005 Based on AJCC/UICC
More informationTalk to Your Doctor. Fact Sheet
Talk to Your Doctor Hearing the words you have skin cancer is overwhelming and would leave anyone with a lot of questions. If you have been diagnosed with Stage I or II cutaneous melanoma with no apparent
More informationAdvances in Surgical Management of Primary Melanoma: Identifying Patients Who Need More than Conventional Wide Local Excision
Advances in Surgical Management of Primary Melanoma: Identifying Patients Who Need More than Conventional Wide Local Excision Christopher J. Miller, MD Director of Penn Dermatology Oncology Center Associate
More informationPublished Ahead of Print on December 14, 2009 as /JCO J Clin Oncol by American Society of Clinical Oncology
Published Ahead of Print on December 14, 2009 as 10.1200/JCO.2009.24.7734 The latest version is at http://jco.ascopubs.org/cgi/doi/10.1200/jco.2009.24.7734 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L
More informationPatricia Chevez-Barrrios AAOOP-USCAP /12/2016
Biomarkers in Ocular Melanoma Patricia Chévez-Barrios, MD Pathology and Genomic Medicine, Houston Methodist Hospital Professor of Pathology and Laboratory Medicine and Ophthalmology, Weill Cornell Medical
More information1/10/2018. Soft Tissue Tumors Showing Melanocytic Differentiation. Overview. Desmoplastic/ Spindle Cell Melanoma
2016 MFMER slide-1 2016 MFMER slide-2 2016 MFMER slide-3 Soft Tissue Tumors Showing Melanocytic Differentiation Andrew L. Folpe, M.D. Professor of Laboratory Medicine and Pathology Mayo Clinic, Rochester,
More informationBenign versus Cancerous Lesions How to tell the difference FMF 2014 Christie Freeman MD, CCFP, DipPDerm, MSc
1 Benign versus Cancerous Lesions How to tell the difference FMF 2014 Christie Freeman MD, CCFP, DipPDerm, MSc Benign lesions Seborrheic Keratoses: Warty, stuck-on Genetics and birthdays Can start in late
More informationTHE SPITZ NEVUS OFTEN POSES
OBSERVATION ONLINE FIRST Melanoma Mimic A Case of Multiple Pagetoid Spitz Nevi KaLynne Harris, MD; Scott R. Florell, MD; Jason Papenfuss, MD; Wendy Kohlmann, MS, CGC; Mona Jahromi, BS; Joshua D. Schiffman,
More informationRadionuclide detection of sentinel lymph node
Radionuclide detection of sentinel lymph node Sophia I. Koukouraki Assoc. Professor Department of Nuclear Medicine Medicine School, University of Crete 1 BACKGROUND The prognosis of malignant disease is
More informationPatient age and cutaneous malignant melanoma: Elderly patients are likely to have more aggressive histological features and poorer survival
MOLECULAR AND CLINICAL ONCOLOGY 7: 1083-1088, 2017 Patient age and cutaneous malignant melanoma: Elderly patients are likely to have more aggressive histological features and poorer survival FARUK TAS
More information